# Influence of maternal or neonatal Vitamin A injection on calf performance and muscle transcriptomics in the cow-calf phase

**Authors:** J. M. Oliveira, D. R. Casagrande, S. A. S. Laura, A. H. A. Horta, A. S. Miranda, T. R. S. Gionbelli, L. H. L. Chalfun, M. M. Ladeira

PMC · DOI: 10.1007/s11250-026-04976-0 · Tropical Animal Health and Production · 2026-03-14

## TL;DR

Injecting vitamin A during late pregnancy or early life improves male calf growth and muscle gene activity.

## Contribution

Maternal vitamin A injection had a stronger impact on muscle gene expression in male calves compared to postnatal injections.

## Key findings

- Male calves from vitamin A-injected mothers had higher average daily gain and weaning weight.
- Maternal vitamin A injection increased expression of genes like RARA, MYF5, and PAX7 in male calves.
- Gene expression differences were more pronounced in males than females.

## Abstract

This study investigated the effects of vitamin A (VA) injection on growth performance, muscle development, and skeletal muscle transcriptomics in calves during the cow-calf phase. Pregnant cows at 250 days of gestation were randomly assigned to one of three treatments: control (CON; no VA injection), VA injection in cows at 250 d of gestation (VAcow), or VA injections in calves at birth and 60 days of age (VAcalf). Calves were weighed at 60 d and weaning. Carcass ultrasound and muscle biopsy were conducted at weaning. Gene expressions were analyzed by RT-qPCR. Male calves in the VAcow group had higher (P = 0.01) ADG than Control males and VA-treated females. Weaning BW was greater (P < 0.01) in VAcalf and VAcow males compared to Control males and VA-treated females. Gene expression analysis revealed that RARA, MYF5, CEBPA, and DLK1 were higher (P ≤ 0.05) expressed in Control and VAcow calves than in VAcalf calves. Expressions of ZNF423 and RXRA tended to be greater (P ≤ 0.09) in VAcow males than in VAcalf males and VA-treated females. The expression of PAX7 was higher (P < 0.01) in VAcow males than in all other groups. Also, IGFR1 expression tended to be greater (P = 0.07) in VAcow males than in Control and VAcalf males and VAcalf females. In conclusion, VA injection during late gestation or early postnatal life improved growth of male calves. Maternal VA injection had a more pronounced effect on muscle gene expression, particularly in male calves.

## Linked entities

- **Genes:** RARA (retinoic acid receptor alpha) [NCBI Gene 5914], MYF5 (myogenic factor 5) [NCBI Gene 4617], CEBPA (CCAAT enhancer binding protein alpha) [NCBI Gene 1050], DLK1 (delta like non-canonical Notch ligand 1) [NCBI Gene 8788], ZNF423 (zinc finger protein 423) [NCBI Gene 23090], RXRA (retinoid X receptor alpha) [NCBI Gene 6256], PAX7 (paired box 7) [NCBI Gene 5081], FCGR1A (Fc gamma receptor Ia) [NCBI Gene 2209]
- **Chemicals:** vitamin A (PubChem CID 445354)

## Full-text entities

- **Genes:** MYF5 (myogenic factor 5) [NCBI Gene 281335], MYH7 (myosin heavy chain 7) [NCBI Gene 282714], PPARD (peroxisome proliferator activated receptor delta) [NCBI Gene 353106] {aka PPAR-beta}, MYH1 (myosin heavy chain 1) [NCBI Gene 281337], FABP4 (fatty acid binding protein 4, adipocyte) [NCBI Gene 281759], LOC536229 (paired box protein Pax-7) [NCBI Gene 536229] {aka PAX7}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 281181] {aka GAPD}, MYOD1 (myogenic differentiation 1) [NCBI Gene 281938] {aka MyoD}, MYF6 (myogenic factor 6) [NCBI Gene 281336] {aka MRF4}, RARA (retinoic acid receptor alpha) [NCBI Gene 534280], DLK1 (delta like non-canonical Notch ligand 1) [NCBI Gene 281117], RXRB (retinoid X receptor beta) [NCBI Gene 504943], GHR (growth hormone receptor) [NCBI Gene 280805], IGF1R (insulin like growth factor 1 receptor) [NCBI Gene 281848] {aka IGFR1}, ZNF423 (zinc finger protein 423) [NCBI Gene 508025], ACTB (actin beta) [NCBI Gene 280979], PDGFRA (platelet derived growth factor receptor alpha) [NCBI Gene 282301], Glyceraldehyde-3-phosphate dehydrogenase [NCBI Gene 786101], PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 281993], CEBPA (CCAAT enhancer binding protein alpha) [NCBI Gene 281677], MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 100139219], MYOG (myogenin) [NCBI Gene 281343], RXRA (retinoid X receptor alpha) [NCBI Gene 507554], RARB (retinoic acid receptor beta) [NCBI Gene 616895], MYH2 (myosin heavy chain 2) [NCBI Gene 788772] {aka MyHC-2a}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 281572] {aka VEGF, VEGF-A, VPF, eVEGF120, eVEGF164}, RARG (retinoic acid receptor gamma) [NCBI Gene 540425]
- **Diseases:** FTAI (MESH:D011681), infection (MESH:D007239), muscle fiber hyperplasia (MESH:D006965)
- **Chemicals:** iodine (MESH:D007455), oxytetracycline (MESH:D010118), Betadine (MESH:D011206), FTAI (-), agarose (MESH:D012685), Retinyl palmitate (MESH:C014794), VA (MESH:D014801), nitrogen (MESH:D009584), RA (MESH:D014212), lipids (MESH:D008055)
- **Species:** Bos taurus (bovine, species) [taxon 9913], Mus musculus (house mouse, species) [taxon 10090], Urochloa decumbens (species) [taxon 240449]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12988903/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12988903/full.md

---
Source: https://tomesphere.com/paper/PMC12988903